Short answer
Corteva (CTVA) filed an 8-K current report with the SEC on November 12, 2026 reporting Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1). Crop Protection revenue $5,536M for nine months, up from $5,519M, indicating near-flat top-line performance.
Corteva 8-K event analysis
AI summary of each reported item and its exhibits
Item EX-99.1 · Exhibit EX-99.1
- Crop Protection revenue $5,536M for nine months, up from $5,519M, indicating near-flat top-line performance
- Nine-month net income attributable to New Corteva fell to $95M from $312M, driven by lower operating income and higher tax expense
- Operating cash flow turned negative at $(1,310)M versus $69M, including $1,548M of pension and OPEB contributions
- Cash declined to $1,722M from $3,685M while long-term debt increased to $2,372M from $1,686M
- Biotelliga acquisition for $66M adds biological crop-protection technology, including $53M of in-process R&D assets
Item EX-99.2 · Exhibit EX-99.2
- Q3 operating EBITDA $299M, margin 17.7%, versus $315M and 17.6% in 2025
- Nine-month operating EBITDA $1.112B, up from $1.046B, with margin expanding to 20.1% from 19.0%
- Q3 GAAP net loss $(14)M, versus $88M income, despite stable operating EBITDA
- Nine-month GAAP income fell to $197M from $406M, reflecting $250M of significant pre-tax charges
- Nine-month operating earnings $610M, up from $425M, highlighting substantial adjustment impact on GAAP results
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Corteva 8-K filings
Get the next CTVA 8-K as it lands
Follow CTVA for push alerts, or ask the research agent what this filing means.